IL264924B2 - 4–4–TRIFLUORO–N–[(1S)–2–[[(7S–5–(2–HYDROXYETHYL)–6–OXO–7H–PYRIDO[2,3–D][3]BENZAZEPIN–7–YL [AMINO]–1–METHYL–2–OXO–ETHYL]BUTANAMIDE or a salt or hydrate thereof for use in the treatment of solid cancer - Google Patents
4–4–TRIFLUORO–N–[(1S)–2–[[(7S–5–(2–HYDROXYETHYL)–6–OXO–7H–PYRIDO[2,3–D][3]BENZAZEPIN–7–YL [AMINO]–1–METHYL–2–OXO–ETHYL]BUTANAMIDE or a salt or hydrate thereof for use in the treatment of solid cancerInfo
- Publication number
- IL264924B2 IL264924B2 IL264924A IL26492419A IL264924B2 IL 264924 B2 IL264924 B2 IL 264924B2 IL 264924 A IL264924 A IL 264924A IL 26492419 A IL26492419 A IL 26492419A IL 264924 B2 IL264924 B2 IL 264924B2
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- hydrate
- dose
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381911P | 2016-08-31 | 2016-08-31 | |
| PCT/US2017/048308 WO2018044662A1 (en) | 2016-08-31 | 2017-08-24 | Dosage regimen for treatment of solid tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL264924A IL264924A (https=) | 2019-04-30 |
| IL264924B1 IL264924B1 (en) | 2023-09-01 |
| IL264924B2 true IL264924B2 (en) | 2024-01-01 |
Family
ID=59772787
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264924A IL264924B2 (en) | 2016-08-31 | 2017-08-24 | 4–4–TRIFLUORO–N–[(1S)–2–[[(7S–5–(2–HYDROXYETHYL)–6–OXO–7H–PYRIDO[2,3–D][3]BENZAZEPIN–7–YL [AMINO]–1–METHYL–2–OXO–ETHYL]BUTANAMIDE or a salt or hydrate thereof for use in the treatment of solid cancer |
| IL305136A IL305136A (en) | 2016-08-31 | 2017-08-24 | Dosage regimen for the treatment of solid tumors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL305136A IL305136A (en) | 2016-08-31 | 2017-08-24 | Dosage regimen for the treatment of solid tumors |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190209581A1 (https=) |
| EP (1) | EP3506905B1 (https=) |
| JP (2) | JP2019526632A (https=) |
| KR (1) | KR102512899B1 (https=) |
| CN (2) | CN109562114A (https=) |
| AU (1) | AU2017321011B2 (https=) |
| BR (1) | BR112019002461A2 (https=) |
| CA (1) | CA3035616A1 (https=) |
| ES (1) | ES2977556T3 (https=) |
| IL (2) | IL264924B2 (https=) |
| MA (1) | MA46086A (https=) |
| MX (1) | MX387397B (https=) |
| SG (2) | SG11201901325UA (https=) |
| WO (1) | WO2018044662A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| JP6911047B2 (ja) | 2016-04-12 | 2021-07-28 | イーライ リリー アンド カンパニー | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 |
| EP3442528B1 (en) | 2016-04-12 | 2021-05-26 | Eli Lilly and Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer |
| JP7194022B2 (ja) | 2016-05-20 | 2022-12-21 | イーライ リリー アンド カンパニー | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| MX2019009552A (es) | 2017-02-17 | 2019-10-02 | Hutchinson Fred Cancer Res | Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios. |
| MX2020004568A (es) | 2017-11-06 | 2020-10-05 | Juno Therapeutics Inc | Combinación de una terapia celular y un inhibidor de gamma secretasa. |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008112249A1 (en) * | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US46206A (en) | 1865-02-07 | Improved vessel for holding petroleum | ||
| US20090149433A1 (en) * | 2007-11-13 | 2009-06-11 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| CN106488775A (zh) * | 2014-07-11 | 2017-03-08 | 基因泰克公司 | Notch途径抑制 |
| TWI609687B (zh) * | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
-
2017
- 2017-08-24 SG SG11201901325UA patent/SG11201901325UA/en unknown
- 2017-08-24 EP EP17761723.0A patent/EP3506905B1/en active Active
- 2017-08-24 CA CA3035616A patent/CA3035616A1/en active Pending
- 2017-08-24 CN CN201780052146.2A patent/CN109562114A/zh active Pending
- 2017-08-24 CN CN202310314953.4A patent/CN116473978A/zh active Pending
- 2017-08-24 SG SG10202107832UA patent/SG10202107832UA/en unknown
- 2017-08-24 WO PCT/US2017/048308 patent/WO2018044662A1/en not_active Ceased
- 2017-08-24 MA MA046086A patent/MA46086A/fr unknown
- 2017-08-24 IL IL264924A patent/IL264924B2/en unknown
- 2017-08-24 KR KR1020197005847A patent/KR102512899B1/ko active Active
- 2017-08-24 AU AU2017321011A patent/AU2017321011B2/en not_active Ceased
- 2017-08-24 IL IL305136A patent/IL305136A/en unknown
- 2017-08-24 BR BR112019002461A patent/BR112019002461A2/pt not_active Application Discontinuation
- 2017-08-24 JP JP2019531873A patent/JP2019526632A/ja active Pending
- 2017-08-24 ES ES17761723T patent/ES2977556T3/es active Active
- 2017-08-24 US US16/328,267 patent/US20190209581A1/en not_active Abandoned
- 2017-08-24 MX MX2019002066A patent/MX387397B/es unknown
-
2022
- 2022-12-27 JP JP2022209634A patent/JP2023052108A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008112249A1 (en) * | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
Non-Patent Citations (3)
| Title |
|---|
| CHRISTOPHE MASSARD,, FIRST-IN-HUMAN STUDY OF LY3039478, A NOTCH SIGNALING INHIBITOR IN ADVANCED OR METASTATIC CANCER, 1 May 2015 (2015-05-01) * |
| EUNICE YUEN,, POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS FOR AN ORAL NOTCH INHIBITOR, LY3039478, IN THE FIRST-IN-MAN STUDY, 1 July 2016 (2016-07-01) * |
| WARREN J. PORTER,, DISCOVERY OF A NOVEL NOTCH INHIBITOR, 16 April 2013 (2013-04-16) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109562114A (zh) | 2019-04-02 |
| EP3506905B1 (en) | 2024-03-20 |
| EP3506905A1 (en) | 2019-07-10 |
| MX387397B (es) | 2025-03-18 |
| BR112019002461A2 (pt) | 2019-05-14 |
| KR102512899B1 (ko) | 2023-03-23 |
| SG11201901325UA (en) | 2019-03-28 |
| AU2017321011B2 (en) | 2023-08-03 |
| CA3035616A1 (en) | 2018-03-08 |
| IL264924A (https=) | 2019-04-30 |
| ES2977556T3 (es) | 2024-08-26 |
| MX2019002066A (es) | 2019-06-03 |
| MA46086A (fr) | 2019-07-10 |
| SG10202107832UA (en) | 2021-09-29 |
| WO2018044662A1 (en) | 2018-03-08 |
| JP2019526632A (ja) | 2019-09-19 |
| IL264924B1 (en) | 2023-09-01 |
| CN116473978A (zh) | 2023-07-25 |
| US20190209581A1 (en) | 2019-07-11 |
| JP2023052108A (ja) | 2023-04-11 |
| AU2017321011A1 (en) | 2019-02-21 |
| KR20190042591A (ko) | 2019-04-24 |
| IL305136A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017321011B2 (en) | Dosage regimen for treatment of solid tumors | |
| JP6963146B1 (ja) | 癌を治療するためのｋｒａｓ阻害剤の投与 | |
| JP2023017922A (ja) | 少なくとも２つの非必須アミノ酸を欠くダイエタリー製品 | |
| JP6716585B2 (ja) | 結腸直腸癌の処置に使用するためのアピリモド | |
| WO2018107173A1 (en) | Glutamine transport inhibitors and methods for treating cancer | |
| CN112955130A (zh) | 包含取代茚满的固体分散体和药物组合物及其制备和使用方法 | |
| JP6855472B2 (ja) | がんを治療するためのｍｄｍ２阻害剤の投与計画 | |
| JP2022500479A (ja) | Ｃｄｃ７阻害剤を含む癌の治療方法 | |
| CA3092079A1 (en) | Methods of treatment of cancer comprising chk1 inhibitors | |
| EP4213852A1 (en) | Non-invasive functional companion assays for oncogene targeted therapy for brain cancer | |
| JP2022532597A (ja) | Ｃｈｋ１阻害剤を使用してがんを治療する方法 | |
| HK40009858A (en) | Dosage regimen for treatment of solid tumors | |
| HK40009858B (en) | Dosage regimen for treatment of solid tumors | |
| NZ791442A (en) | Dosage regimen for treatment of solid tumors | |
| TW202434251A (zh) | 治療癌症之療法 | |
| ES2726401T3 (es) | Uso de inhibidores de HDAC para el tratamiento de la destrucción ósea | |
| US20230233567A1 (en) | Belvarafenib for use in cancer treatment | |
| WO2025217209A2 (en) | Crystalline forms of hdac inhibitor and uses thereof | |
| KR20250171183A (ko) | 암의 예방 또는 치료용 약제학적 조성물 | |
| HK40096504A (en) | Dietary product devoid of at least two non essential amino acid |